News

In a study funded in part by the National MS Society, researchers in Canada and France evaluated medical records and outcomes for people with relapsing MS who had been prescribed interferon beta (1a and 1b) to treat their MS. The researchers compared outcomes for people who had been prescribed interferons compared to those who had not during a specific interval. Using sophisticated statistical methods, they found as a whole that the group that had been exposed to at least 6 months of interferons, but especially to more than three years of interferons, had a lower risk of death during the study period, compared to those who had not been exposed to interferons. This adds to previous evidence suggesting that interferons could improve survival among people with MS. This study was not designed to answer the question of whether this same benefit is seen with other MS disease-modifying therapies.    
 
Read about it on the University of British Columbia’s website
Read the scientific abstract in the journal Brain